CXCR4 and cancer: Anti-LAG3 antibodies and CXCR4-targeted therapies are currently being investigated in clinical trials (NCT03470922, NCT02907099, NCT04177810), and our study provides additional rationale to develop these therapeutic strategies, particularly for cancers that arise from or metastasize to the liver.